NYSE:ADCT - ADC Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $50.00
  • Forecasted Upside: 115.70 %
  • Number of Analysts: 3
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$23.18
▲ +0.97 (4.37%)
1 month | 3 months | 12 months
Get New ADC Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ADCT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ADCT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$50.00
▲ +115.70% Upside Potential
This price target is based on 3 analysts offering 12 month price targets for ADC Therapeutics in the last 3 months. The average price target is $50.00, with a high forecast of $55.00 and a low forecast of $42.00. The average price target represents a 115.70% upside from the last price of $23.18.

Buy

The current consensus among 3 investment analysts is to buy stock in ADC Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/22/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/21/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/19/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/17/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/16/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/16/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/15/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/14/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/14/2021HC WainwrightLower Price TargetBuy$57.00 ➝ $55.00High
i
5/10/2021Morgan StanleyLower Price TargetOverweight$55.00 ➝ $53.00High
i
4/26/2021HC WainwrightBoost Price TargetBuy$48.00 ➝ $57.00High
i
3/23/2021Morgan StanleyLower Price TargetOverweight$56.00 ➝ $55.00Medium
i
3/19/2021HC WainwrightBoost Price TargetBuy$47.00 ➝ $48.00High
i
12/16/2020Morgan StanleyBoost Price TargetOverweight$52.00 ➝ $56.00Medium
i
12/2/2020Stifel NicolausInitiated CoverageHold$42.00High
i
10/29/2020HC WainwrightInitiated CoverageBuy$47.00Low
i
10/13/2020Morgan StanleyLower Price TargetOverweight$53.00 ➝ $52.00Low
i
Rating by Matthew Harrison at Morgan Stanley
6/9/2020Morgan StanleyInitiated CoverageOverweight$53.00High
i
6/9/2020CowenInitiated CoverageOutperformHigh
i
6/9/2020Bank of AmericaInitiated CoverageBuy$45.00High
i
(Data available from 6/14/2016 forward)
ADC Therapeutics logo
ADC Therapeutics SA, a clinical-stage oncology-focused biotechnology company, develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its lead product candidates are loncastuximab tesirine (ADCT-402), an ADC that is in a Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma, and Phase III clinical trial in combination with rituximab to treat relapsed or refractory DLBCL, as well as Phase I/II clinical trial in combination with ibrutinib for relapsed or refractory DLBCL and mantle cell lymphoma; and camidanlumab tesirine (ADCT-301), an ADC that is in a pivotal Phase II clinical trial for the treatment of relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma, and Phase Ib clinical trial for selected advanced solid tumors. The company also develops clinical-stage product candidates, such as ADCT-601 that is in a Phase Ia clinical trial for the treatment of selected advanced tumors; and ADCT-602, and a Phase I/II clinical trial for relapsed or refractory acute lymphoblastic leukemia, as well as preclinical product candidates, including ADCT-701 and ADCT-901 for the treatment of selected advanced solid tumors. It has a collaboration and license agreement with Genmab A/S, Bergenbio AS, and Synaffix B.V. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland.
Read More

Today's Range

Now: $23.18
$22.10
$23.42

50 Day Range

MA: $22.80
$20.38
$26.95

52 Week Range

Now: $23.18
$20.01
$56.59

Volume

278,265 shs

Average Volume

323,117 shs

Market Capitalization

$1.60 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of ADC Therapeutics?

The following sell-side analysts have issued reports on ADC Therapeutics in the last twelve months: HC Wainwright, Morgan Stanley, Stifel Nicolaus, and Zacks Investment Research.
View the latest analyst ratings for ADCT.

What is the current price target for ADC Therapeutics?

3 Wall Street analysts have set twelve-month price targets for ADC Therapeutics in the last year. Their average twelve-month price target is $50.00, suggesting a possible upside of 115.7%. HC Wainwright has the highest price target set, predicting ADCT will reach $55.00 in the next twelve months. Stifel Nicolaus has the lowest price target set, forecasting a price of $42.00 for ADC Therapeutics in the next year.
View the latest price targets for ADCT.

What is the current consensus analyst rating for ADC Therapeutics?

ADC Therapeutics currently has 1 hold rating and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe ADCT will outperform the market and that investors should add to their positions of ADC Therapeutics.
View the latest ratings for ADCT.

What other companies compete with ADC Therapeutics?

How do I contact ADC Therapeutics' investor relations team?

The company's listed phone number is 41 21 653 02 00 and its investor relations email address is [email protected] The official website for ADC Therapeutics is www.adctherapeutics.com.